SCHEMBL347700

SCHEMBL347700

CC(C)CCc1[c]cccc1

nearest known ligand 0.36

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.36
ALDH1A1 P00352 2/20 0.32
AOC3 Q16853 1/20 0.32
ESR1 P03372 1/20 0.30
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
RAB9A P51151 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6887081 0.88 GRIN2D (0.34) DHODHALDH1A1AOC3
SCHEMBL11841129 0.86 HIF1A (0.35) DHODHALDH1A1
SCHEMBL348348 0.86 LMNA (0.42) ALDH1A1
SCHEMBL3178729 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL3672282 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL7186788 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL980256 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL868475 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL5204233 0.85 HIF1A (0.37) ALDH1A1
SCHEMBL3406450 0.85 HIF1A (0.37) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 632 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220393118-A1 TETRADENTATE LIGANDS, GOLD(III) COMPLEXES, PREPARATION METHOD AND USE THEREOF CHE, CHI MING (CN) 2022-12-08 US claimed
EP-4017936-A1 TETRADENTATE LIGANDS, GOLD(III) COMPLEXES, PREPARATION METHOD AND USE THEREOF Che, Chi Ming (HK) 2022-06-29 EP claimed
WO-2021036978-A1 TETRADENTATE LIGANDS, GOLD(III) COMPLEXES, PREPARATION METHOD AND USE THEREOF CHE CHI MING (CN) 2021-03-04 WO claimed
CN-112409243-A Tetradentate ligand, gold (III) complex, and preparation method and application thereof 支志明 2021-02-26 CN claimed
CN-106232120-B Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2- (1H) -ones 爱尔皮奥治疗有限公司 2021-01-08 CN claimed
US-9388135-B2 Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones AERPIO THERAPEUTICS, INC. (US) 2016-07-12 US claimed
US-20150232425-A1 PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES AERPIO THERAPEUTICS, INC. 2015-08-20 US claimed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 EP claimed
CN-101525497-B pyrazoline pyridino-benzo coumarin fluorescent dye derivative and synthesis method and application thereof CHINESE ACAD TECH INST PHYSICS 2012-07-04 CN claimed
CN-101610995-A Novel glucagon receptor antagonists METABASIS THERAPEUTICS INC (US) 2009-12-23 CN claimed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 EP claimed
CN-101525497-A Pyrazoline pyridino-benzo coumarin fluorescent dye derivative and synthesis method and application thereof CHINESE ACAD TECH INST PHYSICS (CN) 2009-09-09 CN claimed
CN-100519520-C Process for preparing sulfidomethyl phenol derivatives GUANGZHOU INST OF CHEMISTRY (CN) 2009-07-29 CN claimed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 WO claimed
CN-1990467-A Process for preparing sulfidomethyl phenol derivatives GUANGZHOU INST OF CHEMISTRY (CN) 2007-07-04 CN claimed
EP-0362649-B1 Radiation-sensitive compositions and their use BASF AG (DE) 1994-03-02 EP claimed
EP-0362644-B1 RADIATION-SENSITIVE COMPOSITIONS AND THEIR USE BASF Aktiengesellschaft (DE) 1993-05-26 EP claimed
CN-118165031-A Nitrile compound, electrolyte, secondary battery and device 蔚来电池科技(安徽)有限公司 2024-06-11 CN disclosed
US-4139537-A 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds COOPER LABORATORIES, INC. (US) 1979-02-13 US disclosed
US-4123538-A (2-Amino-2-oxoethoxy)acetic acid compounds, compositions and methods MCNEIL LABORATORIES, INCORPORATED (US) 1978-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232425-A1 PROCESS FOR PREPARING N-BENZYL-3-HYDROXY-4-SUBSTITUTED-PYRIDIN-2-(1H)-ONES CYP4B1, CYP8B1, HPD DHODH 685/4885ALDH1A1 1501/4885AOC3 608/4885
US-20220393118-A1 TETRADENTATE LIGANDS, GOLD(III) COMPLEXES, PREPARATION METHOD AND USE THEREOF PDCD2L, TTL, TTLL12 DHODH 736/4885ALDH1A1 1432/4885AOC3 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.